Expertise in
5
conditions

Dr. Robert Brown

Hematology | Oncology
Office
5461 Meridian Mark Rd Ste 400, 
Atlanta, GA 
Expertise in
5
conditions
Office
5461 Meridian Mark Rd Ste 400, 
Atlanta, GA 

Overview

Robert Brown is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia.

Dr. Brown is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 13 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in GA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
5461 Meridian Mark Rd Ste 400, Atlanta, GA 30342
Other Locations
Children's Healthcare of Atlanta at Scottish Rite
1001 Johnson Ferry Rd, Atlanta, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2026
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Enrollment Status: Terminated
Publish Date: March 10, 2026
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 3
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Enrollment Status: Terminated
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
An Intrapatient Single Dose and Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Participants With Sickle Cell Disease (SCD)
An Intrapatient Single Dose and Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Participants With Sickle Cell Disease (SCD)
Enrollment Status: Completed
Publish Date: June 10, 2024
Intervention Type: Drug
Study Drug: GBT021601
Study Phase: Phase 1
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
Enrollment Status: Completed
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 4
View 9 Less Clinical Trials

3 Total Publications

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Haematology
Published: January 06, 2021
Similar Doctors
Expertise in
5
conditions
Dr. Carlton Dampier
Hematology | Oncology
Expertise in
5
conditions
Dr. Carlton Dampier
Hematology | Oncology

Children's Healthcare Of Atlanta At Hughes Spalding

35 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (8.9 miles away)
404-785-9800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Carlton Dampier is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Dampier is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Expertise in
9
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
Expertise in
9
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology

Egleston Children's Hospital At Emory

1405 Clifton Rd NE, 
Atlanta, GA 
 (6.9 miles away)
404-785-1112
Languages Spoken:
English
See accepted insurances

Lakshmanan Krishnamurti is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Krishnamurti is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Anemia, and Bone Marrow Transplant.

Expertise in
4
conditions
Dr. Jason Yustein
Hematology | Oncology
Expertise in
4
conditions
Dr. Jason Yustein
Hematology | Oncology

Arthur M. Blank Hospital

2220 N Druid Hills Rd NE, 
Atlanta, GA 
 (4.8 miles away)
404-785-1200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Yustein is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Yustein is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Osteosarcoma, Ewing Sarcoma, Adult Soft Tissue Sarcoma, and Hereditary Retinoblastoma.

Frequently Asked Questions about Dr. Robert Brown

How do I make an appointment with Dr. Robert Brown?

You can book an appointment with Dr. Robert Brown by calling their office at 404-785-3240. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert Brown a top-rated expert for Sickle Cell Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert Brown is classified as an Distinguished expert for Sickle Cell Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert Brown specialize in?

While Dr. Robert Brown is a Hematology, they have specific expertise in Sickle Cell Disease, Congenital Hemolytic Anemia, and Hemoglobinopathy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Robert Brown participate in research or clinical trials?

Yes. Dr. Robert Brown has published 3 articles and abstracts on conditions like Sickle Cell Disease. You can view a list of Dr. Robert Brown's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert Brown accept my insurance?

Dr. Robert Brown accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 404-785-3240 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brown's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile